Generic Drug Pricing - Are Consolidation or Cartels to Blame?
12 PM EST
Drug pricing has been the subject of Congressional inquiries, government investigations, and media attention. Generic drugs have long played an important role in reducing drug prices. Has the recent wave of generic drug company consolidation adversely affected pricing? Are overlap divestitures sufficient? Are prices being fixed, as might be suggested by DOJ's criminal investigation and related civil litigation? Please join our panel of current and former FTC and DOJ enforcers and economists for a lively discussion.
FREE: Antitrust Section Members, Government, Non-profit Employees, Students
$25 Other Non-Members
Explore Section benefits or call 1-800-285-2221 to join. Code RAT14IP25. For this and all upcoming events visit http://ambar.org/atevents.
The ABA is not seeking CLE credit for this program.
Provided all releases are obtained, MP3 recordings of this program will be available to Section members on the Committee Program Audio page.